Keyphrases
3-point
7%
Active Placebo
7%
Active Treatment
15%
Adjusted Means
7%
Antioxidant
7%
Baseline Characteristics
7%
Bradykinesia
7%
Clinical Benefit
15%
Coenzyme Q10
100%
Disability
7%
Disease Progression
7%
Dopamine Neurons
7%
Dopaminergic Therapy
7%
Dopaminergic Treatment
7%
Double-blind Clinical Trial
7%
Drug-induced Parkinsonism
7%
Early Parkinson's Disease
100%
Exclusion Criteria
7%
High Dose
100%
Human Studies
7%
Inclusion Criteria
7%
Mini-Mental State Examination
7%
Mitochondrial Function
7%
North America
7%
Parkinson's Disease
23%
Parkinson's Disease Model
7%
Phase II Study
7%
Placebo
53%
Preclinical Parkinson's Disease
7%
Primary Outcome Measure
7%
Randomized Clinical Trial
100%
Randomized Placebo-controlled Trial
7%
Rest Tremor
15%
Safety Concerns
7%
Stroke History
7%
Study Termination
7%
Treatment Group
7%
Tremor Score
7%
Unified Parkinson's Disease Rating Scale (UPDRS)
30%
Vitamin E
7%
Well-balancing
7%
Medicine and Dentistry
Alpha Tocopherol
7%
Antioxidant
7%
Apoplexy
7%
Bradykinesia
7%
Clinical Trial
7%
Coenzyme Q10
100%
Diagnosis of Parkinson's Disease
7%
Disease Exacerbation
7%
Disease Model
7%
Drug Megadose
100%
Drug Therapy
15%
Group Therapy
7%
Human Study
7%
Limb
7%
Mini-Mental State Examination Score
7%
Parkinson's Disease
100%
Parkinsonism
7%
Placebo
69%
Randomized Clinical Trial
100%
Unified Parkinson's Disease Rating Scale
30%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha Tocopherol
7%
Antioxidant
7%
Bradykinesia
7%
Clinical Trial
7%
Disease Exacerbation
7%
Disease Model
7%
Dopamine Receptor Stimulating Agent
15%
Human Study
7%
Parkinson's Disease
100%
Parkinsonism
7%
Placebo
69%
Randomized Clinical Trial
100%
Ubidecarenone
100%